PRTK News and Press, Paratek Pharmaceuticals Inc. From 08/04/22

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q2 2022 Earnings Call Aug 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q2 2022 Earnings Call Transcript

The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Paratek Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

Paratek Pharmaceuticals, Inc. (PRTK) Q2 2022 Earnings Conference Call August 03, 2022, 16:30 ET Company Participants Sarah Higgins - VP, Controller and Interim Principal Financial & Accounting Officer Evan Loh - CEO & Director Adam Woodrow - President &am...

Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q2 GAAP EPS of -$0.33 beats by $0.01 . Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M . Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and m...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial Guidance BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) --  Paratek Pharmaceutica...

BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022. The audio web...

Buying Penny Stocks on June 22nd? Here’s What You Need to Know As another day of trading penny stocks and blue chips comes, there is a lot for traders to understand. Right now, issues such as inflation and climbing interest rates have caused a major amount of momentum in the stoc...

Paratek Pharmaceuticals (NASDAQ:PRTK) stock jumped 14% postmarket Tuesday after the U.S. FDA granted fast track designation for oral and IV formulations of Nuzyra. The broad-spectrum antibiotic is used to treat pulmonary nontuberculous mycobacterial (NTM) disease caused by both mycobacte...

-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned -- Nonclinical Studies in MAC Initiating BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced the U.S. Food and Drug Administration has gr...

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...